Zucara Therapeutics Inc. is developing ZT-01, a first-in-class therapeutic to prevent insulin-induced hypoglycemia (low blood sugar) in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin (SST), a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with Type 1 diabetes and insulin-dependent Type 2 diabetes (T1D). ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. Zucara has raised US$21M in a Series A financing that provides capital to conduct Phase 1 and 2 clinical trials. Phase 1 trials have shown ZT-01 to be safe and well tolerated and a proof-of-concept study just announced confirmed ZT-01’s mechanism of action in restoring glucagon release in patients with T1D. ZT-01 has the potential to become the first therapeutic designed to prevent hypoglycemia in people with T1D.